ClinicalTrials.gg
CompletedNCT05872035Updated Oct 29, 2024Results posted

Smartphone Enabled Hearing Study

An interventional study of Apple Software and by Audiologist in Hearing, sponsored by Apple Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by Apple Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Validation of non-inferiority between headphone amplification settings determined by a participant and settings established by audiologist best practices in individuals 18 years or older.

02

Conditions studied

  • Hearing
03

In context

Lead sponsor

Apple Inc. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Proficient in written and spoken English, defined by self-report
  • Mild- to moderate- hearing loss as measured by pure tone audiometry (PTA) reference test, or self-report of perceived hearing loss and 15-25 dB HL (by 4PTA)
  • Participants have access to stable internet connection

Exclusion criteria

Exclusion Criteria:

  • Ear anatomy non-conducive to comfortable wear of headphone
  • Active ear disease
  • Cerumen impaction that cannot be removed
  • Sudden loss of hearing (in the preceding 90 days), defined by self-report
  • Self Report of loud environmental sound exposure (e.g., concert; construction site; fireworks) without hearing protection within 72 hours of reference PTA assessed at Clinic Visit 1
  • Tinnitus that impacts one's daily life, defined by self-report
  • Use of cochlear implants
  • Self-reported issues with small or confined spaces such as a single-person enclosed booth, and/or claustrophobia
  • Health technology, fitness, media outlet employees (or spouse of employees), or employees of CRO/sites contracted to execute this study
  • User noted preference to not wear headphone consistently, or charge headphone and smartphone consistently, during field-use
  • Hearing loss >60 dB HL at 0.25-3kHz and >65 dB HL at 4kHz in either ear; assessed during PTA
  • Hearing loss that requires electroacoustic settings which are not acoustically stable in the participant's ear per audiologist judgement
  • Current regular use of hearing aids
  • Active treatment, or treatment in the past 6 months, with either a chemotherapeutic drug for cancer, or radiation therapy to the head or neck region
  • Active treatment, or treatment in the past 6 months, with parenteral aminoglycoside antibiotics
  • In the Investigator's opinion, unable to adhere to study procedures
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    Self-Fit Settings

    Amplification settings established by algorithm and further adjusted by participants per their preference

    Device: Apple Software

  • Active comparator
    Pro-Fit Settings

    Amplification settings established by clinical reference and further adjusted by an audiologist per current best practice

    Device: by Audiologist

Interventions

  • DeviceApple Software

    Amplification settings established by algorithm and further adjusted by participants per their preference

  • Deviceby Audiologist

    Amplification settings established by clinical reference and further adjusted by an audiologist per current best practice

06

What researchers measure

Primary outcomes

  1. International Outcome Inventory for Hearing Aids (IOI-HA) Survey Results

    The IOI-HA survey is a 7-item questionnaire that assesses the effectiveness of hearing aids. It was self-administered to each study participant one time at the third scheduled clinic visit approximately 18-31 days after enrollment. For each participant, the IOI-HA total score (which ranges from 7-35 where higher scores indicate a better outcome) was computed and the mean IOI-HA scores were compared between the Experimental and Reference Groups.

    Time frame: Approximately 18-31 days upon enrollment

07

Results

Posted Oct 29, 2024

Participant flow

Participants were recruited from multiple sites where audiological services were provided.

Participant flow — Overall Study
MilestoneSelf-Fit SettingsPro-Fit Settings
Started5959
Completed5959
Not completed00

Outcome measures

PrimaryInternational Outcome Inventory for Hearing Aids (IOI-HA) Survey Results

The IOI-HA survey is a 7-item questionnaire that assesses the effectiveness of hearing aids. It was self-administered to each study participant one time at the third scheduled clinic visit approximately 18-31 days after enrollment. For each participant, the IOI-HA total score (which ranges from 7-35 where higher scores indicate a better outcome) was computed and the mean IOI-HA scores were compared between the Experimental and Reference Groups.

Time frame:
Approximately 18-31 days upon enrollment
Reported as:
Mean · score on a scale
International Outcome Inventory for Hearing Aids (IOI-HA) Survey Results
score on a scaleSelf-Fit SettingsPro-Fit Settings
International Outcome Inventory for Hearing Aids (IOI-HA) Survey Results25.5 ± 3.0326.6 ± 3.63

Adverse events

Collected over Participants were evaluated by the PI and/or designee(s) at each of the three scheduled clinic visits from the time they signed the ICF until they completed the study (approximately 18-31 days after enrollment).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Self-Fit Settings0/59 (0%)0/59 (0%)0/59 (0%)
Pro-Fit Settings0/59 (0%)1/59 (1.7%)0/59 (0%)
Most frequent serious events
Most frequent serious events
EventSelf-Fit SettingsPro-Fit Settings
Chest PainGeneral disorders0/591/59
Pain in ExtremityMusculoskeletal and connective tissue disorders0/591/59

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Self-Fit SettingsPro-Fit SettingsTotal
<=18 years000
Between 18 and 65 years333568
>=65 years262450
Sex: Female, Male
Sex: Female, Male(Participants)Self-Fit SettingsPro-Fit SettingsTotal
Female303969
Male292049
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Self-Fit SettingsPro-Fit SettingsTotal
Hispanic or Latino112
Not Hispanic or Latino5858116
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Self-Fit SettingsPro-Fit SettingsTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American41014
White5348101
More than one race011
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)Self-Fit SettingsPro-Fit SettingsTotal
United States5959118
Subject Medical History with >10.0% Occurrence
Subject Medical History with >10.0% Occurrence(Participants)Self-Fit SettingsPro-Fit SettingsTotal
Deafness bilateral262349
Hypertension101222
Hypoacusis5611
Tinnitus14418
Four-Frequency Pure Tone Average Results-Full Analysis Set
Four-Frequency Pure Tone Average Results-Full Analysis Set(Participants)Self-Fit SettingsPro-Fit SettingsTotal
15-25 dB HL (No Impairment)121527
26-40 dB HL (Mild Impairment)262652
41-60 dB HL (Moderate Impairment)211839
08

Study locations

1 site
  • IQVIA
    Overland Park, Kansas 66211, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Aug 2023, 3 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion. A results delay was requested in Aug 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
May 24, 2023
StartActual
Apr 20, 2023
Primary completionActual
Aug 17, 2023
CompletionActual
Aug 17, 2023
Results delay requested
Aug 9, 2024
Results first posted
Oct 29, 2024
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05872035
Lead sponsor
Apple Inc.
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
May 24, 2023
Start date
Apr 20, 2023
Primary completion
Aug 17, 2023
Completion
Aug 17, 2023
Results posted
Oct 29, 2024
Last update
Oct 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion